Journal of Medicinal Chemistry · 2016 · 30 citations · 44 references
PharmacyMedicinal ChemistryPharmacologyDrug DiscoveryMolecular PharmacologyStructure-activity RelationshipsHit-to-lead OptimizationLigand BindingPotency OptimizationReceptor PharmacologyReceptor-ligand InteractionsStructure-activity Relationship AnalysisAgonist ActivityG Protein-coupled Receptor Structure-function RelationshipsG-protein-coupled ReceptorsMass Redistribution StudiesPhysicochemical PropertiesPotency ComparisonPotency MeasurementPotency Relationship
A family of 2 H -chromen-2-one derivatives were identified as G protein-coupled receptor-35 (GPR35) agonists using dynamic mass redistribution assays in HT-29 cells. The compounds with 1 H -tetrazol-5-yl in 3-substituted position displayed higher potency than the corresponding carboxyl analogs, and the hydroxyl group in the 7-position also played an important role in GPR35 agonistic activity. 6-Bromo-7-hydroxy-8-nitro-3-(1 H -tetrazol-5-yl)-2 H -chromen-2-one ( 50 ) was found to be the most potent GPR35 agonist with an EC 50 of 5.8 nM. Calculating the physicochemical properties of compounds with moderate to high potency suggested that compounds 30, 50, and 51 showed good druggability. This study provides a novel series of GPR35 agonists, and compound 50 may be a powerful tool to study GPR35.
44
The maximal affinity of ligands
Irwin D. Kuntz, K. Chen, Kim A. Sharp et al. · Proceedings of the National Academy of Sciences · 1999 · 845 citations
Kynurenic Acid as a Ligand for Orphan G Protein-coupled Receptor GPR35
Jinghong Wang, Nicole Simonavicius, Xiaosu Wu et al. · Journal of Biological Chemistry · 2006 · 678 citations · Full text